Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2023 · 10-Q
Revenue$0.00$0.00— vs Q1 2022 Net Income-$4.02M-$4.02MN/M vs Q1 2022 EPS Diluted-$3.53-$3.53no prior Q1 2022 on file Operating Income-$4,105,535N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end